iScience (Feb 2025)
Multilevel plasticity and altered glycosylation drive aggressiveness in hypoxic and glucose-deprived bladder cancer cells
- Andreia Peixoto,
- Dylan Ferreira,
- Andreia Miranda,
- Marta Relvas-Santos,
- Rui Freitas,
- Tim S. Veth,
- Andreia Brandão,
- Eduardo Ferreira,
- Paula Paulo,
- Marta Cardoso,
- Cristiana Gaiteiro,
- Sofia Cotton,
- Janine Soares,
- Luís Lima,
- Filipe Teixeira,
- Rita Ferreira,
- Carlos Palmeira,
- Albert J.R. Heck,
- Maria José Oliveira,
- André M.N. Silva,
- Lúcio Lara Santos,
- José Alexandre Ferreira
Affiliations
- Andreia Peixoto
- Research Center of IPO-Porto (CI-IPOP) / CI-IPOP@RISE (Health Research Network), Portuguese Oncology Institute of Porto (IPO-Porto) / Porto Comprehensive Cancer Center (P.ccc) Raquel Seruca, Porto, Portugal; i3S – Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal; School of Medicine and Biomedical Sciences (ICBAS), University of Porto, Porto, Portugal
- Dylan Ferreira
- Research Center of IPO-Porto (CI-IPOP) / CI-IPOP@RISE (Health Research Network), Portuguese Oncology Institute of Porto (IPO-Porto) / Porto Comprehensive Cancer Center (P.ccc) Raquel Seruca, Porto, Portugal; i3S – Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal; School of Medicine and Biomedical Sciences (ICBAS), University of Porto, Porto, Portugal
- Andreia Miranda
- Research Center of IPO-Porto (CI-IPOP) / CI-IPOP@RISE (Health Research Network), Portuguese Oncology Institute of Porto (IPO-Porto) / Porto Comprehensive Cancer Center (P.ccc) Raquel Seruca, Porto, Portugal; i3S – Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal; School of Medicine and Biomedical Sciences (ICBAS), University of Porto, Porto, Portugal
- Marta Relvas-Santos
- Research Center of IPO-Porto (CI-IPOP) / CI-IPOP@RISE (Health Research Network), Portuguese Oncology Institute of Porto (IPO-Porto) / Porto Comprehensive Cancer Center (P.ccc) Raquel Seruca, Porto, Portugal; i3S – Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal; School of Medicine and Biomedical Sciences (ICBAS), University of Porto, Porto, Portugal; LAQV-REQUIMTE, Department of Chemistry and Biochemistry, Faculty of Sciences, University of Porto, Porto, Portugal
- Rui Freitas
- Research Center of IPO-Porto (CI-IPOP) / CI-IPOP@RISE (Health Research Network), Portuguese Oncology Institute of Porto (IPO-Porto) / Porto Comprehensive Cancer Center (P.ccc) Raquel Seruca, Porto, Portugal; i3S – Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal; School of Medicine and Biomedical Sciences (ICBAS), University of Porto, Porto, Portugal
- Tim S. Veth
- Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, University of Utrecht, Utrecht, the Netherlands; Netherlands Proteomics Center, Padualaan, Utrecht, the Netherlands
- Andreia Brandão
- Research Center of IPO-Porto (CI-IPOP) / CI-IPOP@RISE (Health Research Network), Portuguese Oncology Institute of Porto (IPO-Porto) / Porto Comprehensive Cancer Center (P.ccc) Raquel Seruca, Porto, Portugal
- Eduardo Ferreira
- Research Center of IPO-Porto (CI-IPOP) / CI-IPOP@RISE (Health Research Network), Portuguese Oncology Institute of Porto (IPO-Porto) / Porto Comprehensive Cancer Center (P.ccc) Raquel Seruca, Porto, Portugal
- Paula Paulo
- Research Center of IPO-Porto (CI-IPOP) / CI-IPOP@RISE (Health Research Network), Portuguese Oncology Institute of Porto (IPO-Porto) / Porto Comprehensive Cancer Center (P.ccc) Raquel Seruca, Porto, Portugal
- Marta Cardoso
- Research Center of IPO-Porto (CI-IPOP) / CI-IPOP@RISE (Health Research Network), Portuguese Oncology Institute of Porto (IPO-Porto) / Porto Comprehensive Cancer Center (P.ccc) Raquel Seruca, Porto, Portugal
- Cristiana Gaiteiro
- Research Center of IPO-Porto (CI-IPOP) / CI-IPOP@RISE (Health Research Network), Portuguese Oncology Institute of Porto (IPO-Porto) / Porto Comprehensive Cancer Center (P.ccc) Raquel Seruca, Porto, Portugal; School of Medicine and Biomedical Sciences (ICBAS), University of Porto, Porto, Portugal
- Sofia Cotton
- Research Center of IPO-Porto (CI-IPOP) / CI-IPOP@RISE (Health Research Network), Portuguese Oncology Institute of Porto (IPO-Porto) / Porto Comprehensive Cancer Center (P.ccc) Raquel Seruca, Porto, Portugal; School of Medicine and Biomedical Sciences (ICBAS), University of Porto, Porto, Portugal
- Janine Soares
- Research Center of IPO-Porto (CI-IPOP) / CI-IPOP@RISE (Health Research Network), Portuguese Oncology Institute of Porto (IPO-Porto) / Porto Comprehensive Cancer Center (P.ccc) Raquel Seruca, Porto, Portugal; School of Medicine and Biomedical Sciences (ICBAS), University of Porto, Porto, Portugal; QOPNA & LAQV-REQUIMTE, Department of Chemistry, University of Aveiro, Aveiro, Portugal
- Luís Lima
- Research Center of IPO-Porto (CI-IPOP) / CI-IPOP@RISE (Health Research Network), Portuguese Oncology Institute of Porto (IPO-Porto) / Porto Comprehensive Cancer Center (P.ccc) Raquel Seruca, Porto, Portugal
- Filipe Teixeira
- Centre of Chemistry, University of Minho, Braga, Portugal
- Rita Ferreira
- QOPNA & LAQV-REQUIMTE, Department of Chemistry, University of Aveiro, Aveiro, Portugal
- Carlos Palmeira
- Research Center of IPO-Porto (CI-IPOP) / CI-IPOP@RISE (Health Research Network), Portuguese Oncology Institute of Porto (IPO-Porto) / Porto Comprehensive Cancer Center (P.ccc) Raquel Seruca, Porto, Portugal; Department of Immunology, Portuguese Oncology Institute of Porto, Porto, Portugal; Health School of University Fernando Pessoa, Porto, Portugal
- Albert J.R. Heck
- Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, University of Utrecht, Utrecht, the Netherlands; Netherlands Proteomics Center, Padualaan, Utrecht, the Netherlands
- Maria José Oliveira
- i3S – Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal; School of Medicine and Biomedical Sciences (ICBAS), University of Porto, Porto, Portugal
- André M.N. Silva
- LAQV-REQUIMTE, Department of Chemistry and Biochemistry, Faculty of Sciences, University of Porto, Porto, Portugal
- Lúcio Lara Santos
- Research Center of IPO-Porto (CI-IPOP) / CI-IPOP@RISE (Health Research Network), Portuguese Oncology Institute of Porto (IPO-Porto) / Porto Comprehensive Cancer Center (P.ccc) Raquel Seruca, Porto, Portugal; Health School of University Fernando Pessoa, Porto, Portugal; Department of Surgical Oncology, Portuguese Oncology Institute of Porto, Porto, Portugal
- José Alexandre Ferreira
- Research Center of IPO-Porto (CI-IPOP) / CI-IPOP@RISE (Health Research Network), Portuguese Oncology Institute of Porto (IPO-Porto) / Porto Comprehensive Cancer Center (P.ccc) Raquel Seruca, Porto, Portugal; School of Medicine and Biomedical Sciences (ICBAS), University of Porto, Porto, Portugal; Corresponding author
- Journal volume & issue
-
Vol. 28,
no. 2
p. 111758
Abstract
Summary: Bladder tumors with aggressive characteristics often present microenvironmental niches marked by low oxygen levels (hypoxia) and limited glucose supply due to inadequate vascularization. The molecular mechanisms facilitating cellular adaptation to these stimuli remain largely elusive. Employing a multi-omics approach, we discovered that hypoxic and glucose-deprived cancer cells enter a quiescent state supported by mitophagy, fatty acid β-oxidation, and amino acid catabolism, concurrently enhancing their invasive capabilities. Reoxygenation and glucose restoration efficiently reversed cell quiescence without affecting cellular viability, highlighting significant molecular plasticity in adapting to microenvironmental challenges. Furthermore, cancer cells exhibited substantial perturbation of protein O-glycosylation, leading to simplified glycophenotypes with shorter glycosidic chains. Exploiting glycoengineered cell models, we established that immature glycosylation contributes to reduced cell proliferation and increased invasion. Our findings collectively indicate that hypoxia and glucose deprivation trigger cancer aggressiveness, reflecting an adaptive escape mechanism underpinned by altered metabolism and protein glycosylation, providing grounds for clinical intervention.